BCL2 and acute myeloid leukemia: The second generation BCL-2 inhibitor VEN induced rapid apoptosis in a variety of AML cell line models at nanomolar concentrations and inhibited leukemia progression in vivo in a murine AML xenograft model, by inducing a short (one week) but significant gain in survival when orally administered at a 100 mg/kg dose [34].